In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Vaccine Co. Ltd.

Latest From Japan Vaccine Co. Ltd.

Pharma Power Japan Barely In COVID Vaccines Race. Why?

Despite having multiple world-class pharma companies and innovative research, Japan is notably absent as a source of candidate vaccines for the coronavirus. The pandemic is again throwing into sharp relief past and present challenges around the country's vaccines sector.

Japan Coronavirus COVID-19

Daiichi Sankyo Realigns Japan R&D As Oncology Comes To Fore

Daiichi Sankyo unveils further restructuring moves, this time mainly in its R&D functions in Japan, as part of an ongoing strategic pivot towards oncology.

Japan Cancer

More Vaccines Restructuring As Daiichi's Oncology Pivot Gains Momentum

Daiichi Sankyo makes further vaccine business restructuring moves as it emphasizes oncology amid global generic challenges to its former big seller olmesartan.

Japan Vaccines

GSK Secures EU & Japanese Approvals For Shingrix

Hot on the heels of the FDA approval, GlaxoSmithKline has received the green light for its shingles vaccine Shingrix from both the EU Commission and the Japanese Ministry of Health, Labour and Welfare but it is remaining tightlipped about its commercialization plans.

Approvals Vaccines
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
UsernamePublicRestriction

Register